|
Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes Clinical Trials Resources presented on Clinical Trials Search is not meant to be a substitute for proven health advice, calls or treatment with a real medical. We aren't mDs. Always consult your doctor on Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes Clinical research trials and Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes healthcare trials take place in a lot of of localities throughout the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectiveness of new does drugs. The function of the studies / projects is to figure out specific human medical questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to find cures for all varieties of conditions, like Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes. Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes Clinical Trials and other clinical trials allow volunteers to access health treatment options before they are available to the masses. Many times the subjects receive professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes clinical trial. Human subjects often obtain the finest healthcare possible for their Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes condition. Hazards are a reality, nevertheless, and might include additional or frequent dr. calls, health hazards (potentially life-jeopardizing), and/or the treatment being uneffective. Trials are federally regulated with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes  Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes
Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes
For Condition: Leukemia, Myelocytic, Acute
Status: Suspended
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: 1) Determine the toxicity of infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL) in relapsed patients after allo-stem cell transplants. 2) Quantitate the alloreactivity of DC/ADL and circulating immune effector cells in patients after infusion. 3) Assess efficacy of AML or CML-BC derived dendritic cells and activated lymphocytes in promoting and sustaining remission in patients with relapse after allo-BMT or stem cell transplant.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: Inclusion: - AML (any type except M3) or CIVIL in blast crisis with greater than or equal to 20% bone marrow blasts at the time of related donor marrow or stem cell transplantation or at relapse post transplant. - Willing to undergo a skin biopsy and either a leukodepletion apheresis or an additional marrow aspiration. - Stem cell or marrow donor willing to have apheresis for T-Cell collection. - Written voluntary informed consent must be obtained from patient and donor. Exclusion: - Medical, social or psychologic factors which would prevent the patient from receiving or cooperating with the full course of therapy or understanding the informed consent procedure. - AML FAB subtype M3.
Total Enrollment: 30
Location and Contact Information:
M.D. Anderson Cancer Center
Houston, Texas, 77030-4009
United States
Additional Information:
Study ID Numbers: ID00-034;
Study Start Date: February 2001
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00048100
Other Leukemia, Myelocytic, Acute Studies:
1. Prophylaxis Trial of Posaconazole vs. Standard Azole Therapy for Neutropenic Patients
2. Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes
3. Safety and Efficacy of Hum195/rGel in Patients with Advanced Myeloid Malignancies
4. Randomized double cord blood transplant study
5. Trial to Reduce Alloimmunization to Platelets (TRAP)
Related Studies:
Other Leukemia, Myelocytic, Acute Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes
|
|
|
|
|
|
|
|
